The comments & viewpoints are my own and are not endorsed or necessarily representative of UH CMC, CWRU, NCCN, FDA, NCI, or NRG. They are my personal opinion.
X-torial: Cleaning up the misinformation about @JoeBiden and #ProstateCancer that I am reading everywhere.
The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA @NCCN PCa guidelines, hold leadership in @NRGonc@theNCI@US_FDA and dedicated my career to help men and their families suffering from PCa
@nytimes@WSJ@FoxNews@CNN@NBCNews@Reuters@ASCO@PCFnews @DeptofDefense
I think most thoracic surgeons and thoracic oncologist would welcome an apples to apples comparison of ChemoICI-surgery vs ChemoICI-XRT
Until then, patients deserve the treatment strategy that has been shown in this patient population to have the best outcomes
When speaking with patients we must share the data we have, not the data we think might be
Everyone: “AI is advancing so fast it may soon surpass human intelligence and end the world.”
Me: Wake me when it figures out how to get 180 people onto an airplane in under 40 minutes.
If the machines can solve Zone 7 standing in the aisle while Zone 1 is still boarding, then I’ll start worrying.
I think we have some time. @Delta
NRG GU003 was designed as a dose escalation trial initially planned as a phase 3 superiority trial for bPFS. However during approval gauntlet was changed to more functionally a phase 2 in size with QOL endpoint. Very valuable trial nonetheless as it showed us:
- 3rd dose escalation RCT that shows no improvement in post op RT
- dose escalation often increased tox/decrease QOL
I continue to use 52.5-55 Gy in 20 with excellent results. Been used for nearly 15 years in UK.
A growing body of evidence suggests millions of surgeries performed each year are unnecessary. They cause needless physical pain and financial stress—and are a terrible waste of resources
Make that THREE papers this week! 🚨
RAPTOR is out: 3,120 men & 11 RCTs. After RT alone, being BCR-free at 5y marked a functional-cure benchmark (8y DM 6.6%; 10y PCSM 2.5%). W/ ADT, late metastatic risk persisted.
https://t.co/LfyPWnfJ5c @AmarUKishan@DrSpratticus@alison_tree
📣 When #RadOnc finds its voice! ☢️
Different institutions. Different perspectives. One community — connecting, communicating & sharing the stories and science that move our field forward 🚀
We ❤️ #radonc
We ❤️ our #patients
And yes… #WeWhoCurie 😉
@ASTRO_org@ASTRO_Chair
Mark- median followup is 8 yrs and curves together. You are simply looking at the issue of PSA endpoints in setting of ADT.
More importantly you are including treatment effect of nodal RT.
Focus on arm 1 vs 2 which is what we are talking about- PAM50 is a predictive biomarker. Statistically it is, functionally it is, mechanistically it is.
Excited to share our new study describing uRARE-seq, a tumor-naive #LiquidBiopsy method for analyzing urine cell-free RNA (cfRNA) in #BladderCancer and other genitourinary cancers. Out today in @NatureMedicine 🧵 1/16 https://t.co/qq4IP8kQPB
Bladder preservation deserves a larger place in MIBC research. More randomized trials should be built around improving trimodality therapy, systemic integration, and long-term bladder-intact survival. What should we test next? @OncoAlert@OpenMedicineHQ@Uromigos@urotoday
Respectfully disagree as the KM curves for MFS superimposed and the bPFS curves come back together which is expected with time to T recovery.
Bottom line it is a predictive biomarker by all accounts. We have been waiting decades for this and it’s here and validated in multiple trials. Time to stop hurting men with overuse of ADT when POSEIDON Lancet study shows most don’t need it anyways.
Another @RadOncUH PGY-4 with an 🎤🔥oral presentation today! @SamLM_MD killing it presenting the ✅feasibility of planning on HyperSight CBCT on TrueBeam in a prospective trial- @SiemensHealth Varian CMO @DrDee2014 & physics PI @APrice_BeamOn both front row, cheering him on!
NCT05975619
@RadOncUH PGY-4 @QingLi_MDPhD 🔥crushing it with an(other) 🎤oral presentation this morning on her #HolmanPathway work on how RT modulates HER2 expression and trastuzuman deruxtecan response in HER2 low metastatic breast cancer.
#bcsm@TyMillerLab
SYMPHONY (Salvage RadiotherapY Multi-arm biomarker and PSMA-guided HarmONY) -- discussed by @DrSpratticus during the #ASTRO26 Use of Novel Biomarkers in GU Cancers session
Impressive NRG led (STAMPEDE-like) platform in the approval process for answering several key questions
@urotoday